Breast cancer is the most frequent malignancy diagnosed in women worldwide. After an initially successful treatment, the main cause of breast cancer related mortality remains cancer recurrence. During the time between remission and relapse to active disease (Disease-Free Survival, DFS), quiescent cancer cells persist in a state referred to as cellular dormancy. The molecular mechanisms involved in the transitions between dormancy and active disease remain obscure. Kaplan-Meier analyses of all intrinsic molecular subtypes of breast cancer revealed that increased expression of Unkempt (UNK) is associated with longer DFS periods in treated patients. UNK is a conserved zinc-finger protein that functions by binding target mRNAs in a sequence-specific manner and reducing protein production. Expression analyses of breast cancers using the cBioportal for Cancer Genomics revealed a group of genes that showed inverse expression from UNK, and further Kaplan-Meier analyses showed that increased expression of a subset of these genes was associated with reduced DFS. We hypothesized that this subset of genes may contain targets of UNK inhibition in breast cancer cells. UNK has one ortholog in C. elegans,
unk-1. As many underlying molecular pathways are conserved between mammalian and nematode development, we hypothesized that a functional model for cancer cellular dormancy could be the transition of C. elegans into dauer diapause, and that C. elegans could provide a robust readout for genetic analysis of UNK targets involved in breast cancer. While in dauer, progenitor cells remain multipotent and quiescent, similar to dormant cancer stem cells. Previous work from the Karp laboratory has shown that
unk-1 is involved in determination of cell fate, and that
unk-1(0) dauer larvae aberrantly express the adult cell-fate marker
col-19p::gfp. We are using RNAi of C. elegans orthologs of the inversely expressed putative UNK targets to screen
unk-1(0) dauer larvae for suppression of the
col-19p::gfp expression phenotype. By identifying potential targets of UNK inhibition, surrogate pharmacological inhibitors could be developed that would improve DFS when used as combination therapeutics in breast cancer.